Published in Dig Dis Sci on October 31, 2008
Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol (2015) 0.75
Chronic hepatitis B. Hepatology (2007) 13.75
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology (1998) 2.67
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology (2001) 2.62
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int (2005) 2.46
Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. J Biol Chem (1992) 1.91
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology (2000) 1.78
Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol (2002) 1.74
Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. Intervirology (2001) 1.65
Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology (2003) 1.48
Determinants for sustained HBeAg response to lamivudine therapy. Hepatology (2003) 1.38
Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol (2003) 1.03
The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. J Clin Virol (2002) 1.02
Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat (2002) 1.00
Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology (2005) 0.98
Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol (2005) 0.82
Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology (2014) 2.14
Overexpression of AtMYB44 enhances stomatal closure to confer abiotic stress tolerance in transgenic Arabidopsis. Plant Physiol (2007) 2.08
Pneumoretroperitoneum following acupuncture. J Altern Complement Med (2008) 2.01
How good is cola for dissolution of gastric phytobezoars? World J Gastroenterol (2009) 1.96
Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2004) 1.70
Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol (2009) 1.66
Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B. J Gastroenterol Hepatol (2011) 1.63
Healthy range for serum ALT and the clinical significance of "unhealthy" normal ALT levels in the Korean population. J Gastroenterol Hepatol (2011) 1.63
A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int (2013) 1.57
[Clinicopathologic characteristics of patients who underwent curative additional gastrectomy after endoscopic submucosal dissection for early gastric cancer or adenoma]. Korean J Gastroenterol (2012) 1.57
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis]. Korean J Gastroenterol (2012) 1.46
Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. J Gastroenterol Hepatol (2012) 1.45
[Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy]. Korean J Gastroenterol (2013) 1.43
Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol (2009) 1.43
[Clinical features and prognosis of primary biliary cirrhosis in Korea]. Korean J Hepatol (2010) 1.43
Alteration of sphingolipid metabolism and pSTAT3 expression by dietary cholesterol in the gallbladder of hamsters. Arch Pharm Res (2009) 1.42
HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma. J Clin Gastroenterol (2011) 1.40
[Clinical features of non-alcoholic fatty liver disease in cryptogenic hepatocellular carcinoma]. Korean J Gastroenterol (2014) 1.39
Effects of sphingolipid synthesis inhibition on cholesterol gallstone formation in C57BL/6J mice. J Gastroenterol Hepatol (2010) 1.38
Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J Biol Chem (2003) 1.35
Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology (2007) 1.33
Ectopic opening of the common bile duct in the duodenal bulb: clinical implications. Gastrointest Endosc (2003) 1.28
PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol (2008) 1.27
Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology (2007) 1.21
Prevalence of gastroesophageal reflux disease symptoms and uninvestigated dyspepsia in Korea: a population-based study. Dig Dis Sci (2007) 1.20
A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. Clin Mol Hepatol (2012) 1.16
Effects of the temporary placement of a self-expandable metallic stent in benign pyloric stenosis. Gut Liver (2013) 1.15
A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol (2006) 1.08
Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver (2012) 1.08
The societal burden of HBV-related disease: South Korea. Dig Dis Sci (2009) 1.06
Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol (2012) 1.06
Prevalence of clonorchiasis in patients with gastrointestinal disease: a Korean nationwide multicenter survey. World J Gastroenterol (2009) 1.06
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2009) 1.06
Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int (2011) 1.05
Pseudomelanosis ilei associated with ingestion of charcoal: case report and review of literature. Dig Endosc (2010) 1.04
Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int (2010) 1.03
Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J Clin Gastroenterol (2013) 1.03
The prevalence of and risk factors for Barrett's esophagus in a Korean population: A nationwide multicenter prospective study. J Clin Gastroenterol (2009) 1.02
A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology (2006) 1.02
Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient. Gut Liver (2010) 1.02
Genetic analysis of HAV strains isolated from patients with acute hepatitis in Korea, 2005-2006. J Med Virol (2008) 1.02
Covered self-expandable metal stents are more associated with complications in the management of malignant colorectal obstruction. Surg Endosc (2013) 1.02
Factors influencing the severity of acute viral hepatitis A. Korean J Hepatol (2010) 1.00
Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol (2010) 0.98
Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study. Gut Liver (2009) 0.97
Clinical features of acute viral hepatitis B in Korea: a multi-center study. Korean J Hepatol (2011) 0.97
Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data. J Clin Gastroenterol (2011) 0.96
Significance of anti-HCV signal-to-cutoff ratio in predicting hepatitis C viremia. Korean J Intern Med (2009) 0.96
[Clinical features of acute hepatitis A in recent two years]. Korean J Gastroenterol (2008) 0.95
Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol (2013) 0.95
Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. J Korean Med Sci (2009) 0.95